Cargando…
Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response
Heat shock protein 90 (Hsp90) is a potential oncogenic target. However, Hsp90 inhibitors in clinical trial induce heat shock response, resulting in drug resistance and inefficiency. In this study, we designed and synthesized a series of novel triazine derivatives (A1‐26, B1‐13, C1‐23) as Hsp90 inhib...
Autores principales: | Liu, Peng, Chen, Xiangling, Zhu, Jianming, Li, Bo, Chen, Zhaoqiang, Wang, Guimin, Sun, Haiguo, Xu, Zhijian, Zhao, Zhixin, Zhou, Chen, Xie, Chengying, Lou, Liguang, Zhu, Weiliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437812/ https://www.ncbi.nlm.nih.gov/pubmed/30976475 http://dx.doi.org/10.1002/open.201900055 |
Ejemplares similares
-
X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response
por: Zhao, Zhixin, et al.
Publicado: (2016) -
Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016) -
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin
por: Xie, Chengying, et al.
Publicado: (2017) -
Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021) -
Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
por: Zagouri, Flora, et al.
Publicado: (2012)